Compare AbbVie Inc (ABBV) vs WD 40 Company (WDFC) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

WDFC trades at $246.45, up 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 55.67% gross margins and recently beat Q1 2026 earnings expectations. Recent corporate developments include executive leadership appointments and a $1.02 quarterly dividend declaration. Revenue growth remains steady with 2026 projections at $636 million, though net income is expected to decline to $80 million.

WDFC presents a mixed investment case with premium valuation metrics (P/E 41.82) offset by consistent profitability and dividend payments. The primary risk involves earnings volatility as seen in recent quarterly misses, while analyst sentiment remains cautious with 71% hold ratings. Upside potential exists if the company can maintain its recent earnings beat trend and execute on growth initiatives.